György Kéri was a Hungarian biochemist, professor and Doctor of Biological Sciences. His major field of research was signal transduction therapy and he participated in the development of novel drug discovery technologies and drug candidates that entered the clinical development process.
1979-1988: Research scientist and Senior research scientist of First Institute of Biochemistry, Semmelweis University Medical School and Hungarian Academy of Sciences
1988-1994: Head of Peptide Research Laboratory, Associate Professor of Biochemistry, Joint Research Organization of the Hungarian Academy of Sciences and Semmelweis University Medical School, The First Institute of Biochemistry
1994-2008: Head of Peptide Biochemistry Research Group and Rational Drug Design Laboratory, Professor of Biochemistry, Department of Medicinal Chemistry, Semmelweis Medical University
1999–present: CEO and CSO of Vichem Chemie Research Ltd.
2001-2012: Chairman of Rational Drug Design Laboratories Co-operation Research Center, Semmelweis University
2002-2008: Curator of Office for Subsidised Research Units of Hungarian Academy of Sciences
2008-2012: Head of Signal Transduction Therapy Laboratory at Semmelweis University
2012–present: Head of Pathobiochemistry Research Group of Hungarian Academy of Sciences at Semmelweis University, Department of Medical Chemistry
Research
György Kéri was an internationally recognized expert on signal transduction therapy and personalized therapy. His pioneering work focused on the utilization of signal transduction therapy approach in the pharmaceutical research. He achieved outstanding results in the research and development of peptide hormone derivatives and kinase inhibitors as antitumor agents. He was involved in the development of a signal-inhibiting somatostatin peptide compound, which reached Phase II clinical trials, and SU101, which reached Phase III clinical trials. Vichem – the company he co-founded in 1999 – developed a kinase inhibitor library, and a hit finding technology called Nested Chemical Library™ technology and an allosteric library for inhibiting protein-protein interactions. He has developed at Vichem the DriverHit Library™ for inhibiting the signaling pathways activated by cancer driver genes or mutated tumor suppressor genes. He also participated with German researchers in the development of a new proteomic technology which makes it possible to identify unknown targets in the signal transduction network or the interacting enzymes of the metabolom. Over a hundred international patents or patent applications can be linked to his name, while he is a co-author of more than 250 publications in international scientific journals and several book chapters.
AXL is a potential target for therapeutic intervention in breast cancer progression
Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle
Proteomics strategy for quantitative protein interaction profiling in cell extracts
Integrating molecular diagnostics into anticancer drug discovery
Development of a Cell Selective and Intrinsically Active Multikinase Inhibitor Bioconjugate
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance BIOCHEMICAL PHARMACOLOGY 84: 260-267, 2012
Developing FGFR4 inhibitors as potential anticancer agents via in silico design, supported by in vitro and cellbased (co-author CURRENT MEDICINAL CHEMISTRY 20:1203-1217, 2013
